Beckman Coulter Life Sciences is taking actions in the best interests of our associates, customers, and business partners as we navigate the growing threats of the 2019 Novel Coronavirus disease (COVID-19). Learn more

Surpassing industry standards for yield and purity of cfDNA, Apostle MiniMax™ is a magnetic nanoparticle-based kit to extract cfDNA from plasma utilizing manual or automated workflows. Due to limited cfDNA concentration, sufficient yield for next-generation sequencing (NGS) or other downstream applications can require higher volumes of plasma. As the volume increases, issues such as recovery efficiency and workflow complexity often arise. Plasma contains a host of contaminants which are problematic at this scale and can reduce assay sensitivity. Apostle MiniMax™ technology performs reliably across a range of volume inputs, consistently recovering high quantities of cfDNA, while effectively removing contaminants.

"Beckman Coulter Life Sciences is committed to working collaboratively with our customers to find the best technologies to meet their complex needs. We have listened to their ongoing challenges in working with cfDNA and sought to find ways to effectively combat those issues. This includes recognizing that an innovative product from a startup like Apostle is the best technology to address these needs," said Steve Wowk, Director of Genomics, Beckman Coulter Life Sciences.

"Beckman Coulter Life Sciences established global presence and commitment to life sciences makes them an ideal collaborator to provide access to our innovative nucleic acid isolation products to customers around the globe," said David Ge, President and CEO, Apostle Inc.

Apostle Inc.

Apostle Inc. is a biotechnology company in Menlo Park, CA. Apostle focuses on research, development, licensing, and sales of novel technologies, and the related intellectual properties, products, and services for diagnosis and treatment of human diseases. Apostle is dedicated to fundamentally improving the accuracy and efficiency of liquid biopsy—the testing of circulating free DNA (cfDNA)—in early cancer detection or other clinical applications such as noninvasive prenatal testing (NIPT), tests for infectious diseases.

* The Advances in Genome Biology and Technology (AGBT) General Meeting is being held in Florida, USA, from February 27 to March 2, 2019

The listed regulatory status for products correspond to one of the below:
IVD: In Vitro Diagnostic Products. These products are labeled "For In Vitro Diagnostic Use."
ASR: Analyte Specific Reagents. These reagents are labeled "Analyte Specific Reagents. Analytical and performance characteristics are not established."
CE: Products intended for in vitro diagnostic use and conforming to European Directive (98/79/EC). (Note: Devices may be CE marked to other directives than (98/79/EC)
RUO: Research Use Only. These products are labeled "For Research Use Only. Not for use in diagnostic procedures."
LUO: Laboratory Use Only. These products are labeled "For Laboratory Use Only."
No Regulatory Status: Non-Medical Device or non-regulated articles. Not for use in diagnostic or therapeutic procedures.

Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.